Enclomiphene FDA Status in 2026: Where Approval Actually Stands and Why Pharmacies Still Compound It

Is enclomiphene FDA-approved in 2026?

No, enclomiphene is not FDA-approved as of 2026. No enclomiphene citrate product holds FDA approval for any indication in the United States. The most advanced regulatory effort was Repros Therapeutics' Androxal program, which submitted a New Drug Application in late 2015, received a Complete Response Letter from the FDA in 2016 requesting additional efficacy evidence, and ultimately ended when Repros filed for Chapter 11 bankruptcy in 2018. The active development program in 2026 is Marius Pharmaceuticals' RESTORE Phase 3 trial, which is recruiting at multiple U.S. sites.

Despite the lack of approval, enclomiphene is widely available — almost entirely through 503A and 503B compounding pharmacies dispensing patient-specific or office-stock preparations under licensed prescriptions. That arrangement is legal when the prescriber-patient relationship and pharmacy compounding rules are followed; it sits in a regulatory mosaic shaped by Section 503A of the Federal Food, Drug, and Cosmetic Act, FDA's bulk drug substance review process, and ongoing FDA Drug Compounding Advisory Committee deliberations. This article walks through the full regulatory history, the current RESTORE trial status, the compounding legality framework, and what patients on enclomiphene in 2026 should understand about where the drug actually stands.

What enclomiphene is and how it works

Enclomiphene is the trans-isomer of clomiphene citrate. Clomiphene, sold as Clomid for ovulation induction in women, is actually a mixture of two stereoisomers — enclomiphene (trans) and zuclomiphene (cis). The two isomers behave differently. Enclomiphene is the more potent estrogen receptor antagonist at the hypothalamus and is responsible for most of the desired luteinizing hormone (LH) and follicle-stimulating hormone (FSH) elevation seen on clomiphene therapy. Zuclomiphene is more estrogenic, has a longer half-life on the order of weeks, and is implicated in many of the off-target effects (mood changes, visual disturbances, lingering estrogenic activity) reported in long-duration clomiphene use.

The mechanism in plain terms: enclomiphene blocks estrogen feedback at hypothalamic estrogen receptors. With that brake removed, the hypothalamus releases more gonadotropin-releasing hormone (GnRH), which drives the anterior pituitary to release more LH and FSH, which in turn signal the testes to produce more endogenous testosterone and to maintain spermatogenesis. The drug is a selective estrogen receptor modulator (SERM), and it acts upstream of the testes — not at the testicular receptor where HCG acts.

For a deeper mechanistic and clinical comparison with TRT, see enclomiphene vs TRT and Clomid vs TRT. The mechanism distinction matters for the regulatory story below: the FDA approval pathway hinges on whether enclomiphene's sperm-preservation claim — the feature that differentiates it from approved testosterone products — has adequate efficacy evidence.

Repros Therapeutics, Androxal, and the original NDA

The first real attempt at FDA approval came from Repros Therapeutics, a small-cap biotech based in The Woodlands, Texas. Repros licensed enclomiphene citrate in the early 2000s and developed it under the brand name Androxal for the treatment of secondary hypogonadism in men. The clinical premise was straightforward: men with low testosterone secondary to hypothalamic-pituitary dysfunction (rather than primary testicular failure) should respond to a SERM that lifts endogenous gonadotropins, with the bonus that — unlike exogenous testosterone — endogenous-driven therapy preserves sperm parameters and intratesticular testosterone.

Repros built a dedicated Phase 3 program around this hypothesis. The two pivotal trials, ZA-301 and ZA-302, were designed as parallel randomized double-blind multicenter studies enrolling overweight men with secondary hypogonadism, comparing once-daily Androxal to placebo and to a testosterone gel comparator. The primary endpoint pair was (1) restoration of morning total testosterone into the eugonadal range and (2) preservation of sperm concentration relative to the gel comparator.

The Phase 3 readouts were reported in 2014 and 2015. Across the program, Androxal met the testosterone restoration endpoint convincingly. The sperm concentration co-endpoint, which carried the differentiating claim against existing testosterone therapies, produced a more nuanced data picture across pre-specified analysis populations. Repros filed the New Drug Application with the FDA in late 2015. The NDA was assigned a standard review timeline.

FDA approval timeline (regulatory milestones)

The Phase 3 trials: ZA-301 and ZA-302

Understanding the FDA decision means understanding the trial design Repros used. The two Phase 3 trials were designed as parallel pivotal studies enrolling overweight men (BMI typically 25 to 42) aged 18 to 60 with confirmed secondary hypogonadism (low morning total testosterone with inappropriately normal or low LH and FSH). Patients were randomized to enclomiphene 12.5 mg or 25 mg daily, placebo, or in a separate sub-study a testosterone gel comparator.

The pre-specified primary efficacy endpoints were:

• Restoration of average 24-hour serum total testosterone into the eugonadal reference range at six months.
• Sperm concentration preservation relative to the testosterone gel comparator (the differentiating claim that distinguished Androxal from the existing FDA-approved TRT formulations).

Across the ZA-301 and ZA-302 readouts reported in 2014 to 2015, enclomiphene met the testosterone restoration endpoint at both dose levels with statistical significance. The trial reports cited LH and FSH increases in line with the upstream mechanism, and a generally favorable safety profile (no signal that exceeded what was expected from the SERM class). Sperm parameter preservation, where statistical comparisons against testosterone gel were made, generally favored enclomiphene — consistent with the mechanism, since gel-driven exogenous testosterone suppresses LH and FSH while enclomiphene raises them.

Where the trial readout became regulatorily delicate was in the specific population, endpoint definitions, and analysis subsets the FDA had pre-specified during End-of-Phase 2 discussions. Repros disclosed in subsequent 10-K filings and investor calls that the FDA reviewers raised concerns about the consistency of the sperm preservation effect across pre-specified populations and about the magnitude of effect needed to support a differentiating label. The agency's ultimate position was that the differentiating claim required additional supporting evidence — the trigger for the Complete Response Letter described below.

Phase 3 readout — primary endpoint outcomes (high-level)

The 2016 FDA Complete Response Letter

In 2016, the FDA issued a Complete Response Letter (CRL) on the Androxal NDA. A CRL is the FDA's formal communication to a sponsor that an application is not approved in its current form, with specific deficiencies the sponsor must address before resubmission. CRLs are not public documents; their contents become public only when the sponsor discloses them, typically through SEC filings if the sponsor is publicly traded.

Repros disclosed the CRL through SEC filings and investor communications. The headline message: the FDA concluded that the existing Phase 3 evidence did not adequately support the sperm-preservation claim that would differentiate Androxal from approved testosterone products. The agency requested additional clinical evidence — most plausibly read as another adequately powered trial or trials — focused on the differentiating efficacy claim. The CRL did not raise new safety concerns of magnitude.

That distinction matters because it changes how the public should read the regulatory outcome. A CRL based on safety would imply the drug is dangerous; a CRL based on efficacy implies the drug works for what it does, but the sponsor has not yet shown what they claim makes it different. Enclomiphene's CRL was the second kind — a request for more evidence on a specific labeling claim, not a finding that the drug was unsafe or ineffective at restoring testosterone.

For Repros, the practical consequence was severe. The cost of running additional Phase 3 trials sufficient to satisfy the FDA, combined with the company's capital position, was prohibitive. Subsequent 10-K filings discussed strategic alternatives including partnership and asset sale, and the Androxal program effectively paused while the company explored those options.

Repros bankruptcy and the IP transfer

In August 2018, Repros Therapeutics filed for Chapter 11 reorganization in the U.S. Bankruptcy Court for the Southern District of Texas. The Chapter 11 process resulted in a sale of substantially all of the company's assets — including the enclomiphene/Androxal intellectual property, clinical data, regulatory dossier, and trade secrets — to Allergan in 2019, which was subsequently acquired by AbbVie.

The Androxal program was not a strategic priority for AbbVie's post-Allergan portfolio, and the IP was eventually divested. Marius Pharmaceuticals — a Raleigh-based specialty company best known for Kyzatrex (oral testosterone undecanoate, FDA-approved in 2022) — acquired the Androxal IP and the related clinical asset package. Marius announced its plans to advance enclomiphene through a new Phase 3 program — RESTORE — designed to address the FDA's prior CRL deficiencies.

For context on Marius's existing oral testosterone work and how oral TRT differs from enclomiphene mechanically, see oral TRT compared: Jatenzo vs Kyzatrex vs Tlando.

The RESTORE trial: Marius Pharmaceuticals' new Phase 3 program

RESTORE is the active Phase 3 development program for enclomiphene in 2026. Marius Pharmaceuticals positions RESTORE as a redesigned trial intended to address the specific deficits the FDA cited in the 2016 CRL while also reflecting an updated trial population and updated regulatory expectations a decade after the original Repros readout.

Key features the public record indicates about RESTORE:

• Indication: secondary hypogonadism in adult men.
• Trial design: randomized, double-blind, placebo-controlled Phase 3 — consistent with FDA expectations for a new androgen pathway therapeutic.
• Endpoints: testosterone restoration plus efficacy endpoints structured around the original CRL feedback. The differentiation logic versus existing TRT remains intact.
• Site list: multiple U.S. clinical sites listed as recruiting on ClinicalTrials.gov as of 2026, with continued site activation expected.
• Regulatory pathway: standard 505(b)(1) NDA pathway anticipated.

The most current details — including the assigned NCT identifier, exact eligibility criteria, primary endpoint definitions, sample size, recruitment status, and participating sites — are maintained on ClinicalTrials.gov. Patients or prescribers evaluating RESTORE participation should reference that public registration directly, since trial parameters can be updated during the recruitment period.

RESTORE recruitment status (illustrative)

Compounded enclomiphene vs FDA-approved enclomiphene

These two terms cause regular confusion. They are not interchangeable.

FDA-approved enclomiphene would mean an enclomiphene product that has gone through an NDA, demonstrated safety and efficacy in adequate and well-controlled trials, received FDA approval, and is manufactured under current Good Manufacturing Practice (cGMP) at an FDA-inspected facility, with FDA-reviewed labeling, formal post-marketing safety surveillance, and a defined indication. As of 2026, no enclomiphene product holds this status.

Compounded enclomiphene means an enclomiphene preparation made on demand by a state-licensed compounding pharmacy. The pharmacy purchases bulk active pharmaceutical ingredient (API), combines it with excipients, and produces capsules, troches, or other dosage forms based on a prescriber's order. Compounding is a recognized practice of pharmacy, but it is fundamentally different from manufacturing in regulatory terms — there is no FDA approval of the formulation, no required clinical trial dossier, and no required post-market surveillance program.

Compounded vs FDA-approved — what is and is not the same

503A vs 503B compounding and where enclomiphene sits

Compounding pharmacy regulation in the United States is divided into two categories created by the Drug Quality and Security Act of 2013, which added Section 503B to the Federal Food, Drug, and Cosmetic Act after the 2012 New England Compounding Center meningitis tragedy that killed more than 60 patients.

503A pharmacies

Section 503A of the Federal Food, Drug, and Cosmetic Act describes traditional compounding pharmacies that produce patient-specific preparations on receipt of a valid prescription. These pharmacies are state-licensed (state boards of pharmacy are the primary regulators) and operate under United States Pharmacopeia (USP) chapter standards. They are not required to register with the FDA as outsourcing facilities and do not undergo cGMP inspection in the same way drug manufacturers do.

For a 503A pharmacy to compound enclomiphene legally, the substance must be either (1) a component of an FDA-approved drug, (2) on the FDA bulks list, or (3) the subject of a USP monograph. Enclomiphene's status as a stereoisomer of clomiphene (which is a component of the FDA-approved Clomid) gives it a regulatory hook that many 503A pharmacies have relied on, though the FDA has revisited bulks list determinations periodically.

503B outsourcing facilities

Section 503B describes outsourcing facilities that produce sterile and non-sterile compounds in larger quantities, often for office stock rather than individual patients. These facilities register with the FDA, undergo cGMP inspection, and submit adverse event reports. Their bulks list framework is separate from the 503A list and has its own FDA review process.

The interim 503B bulks list — used by FDA during the rulemaking period for the formal 503B bulks list — has historically included substances under FDA review. Enclomiphene's status on the interim list and any subsequent formal list determinations have been the subject of FDA Drug Compounding Advisory Committee (PCAC) review meetings. The committee's votes and the FDA's decisions on bulk substances directly affect which 503B facilities can continue producing enclomiphene office stock.

Where enclomiphene sits in 2026

In practical terms, enclomiphene is widely compounded by both 503A pharmacies and certain 503B outsourcing facilities as of 2026. The legal anchor for compounding rests on (a) the patient-specific prescription requirement under 503A, (b) the bulk drug substance review process under 503B, and (c) the absence of an FDA-approved enclomiphene product (compounding rules generally restrict making compounded versions of substances that essentially copy approved drugs).

That last condition is important. The day an FDA-approved enclomiphene product launches, the legal landscape for compounded enclomiphene changes. Compounding pharmacies generally cannot produce essentially copy compounds of commercially available approved products outside specific exceptions. RESTORE's eventual outcome will determine that pivot point.

Is compounded enclomiphene legal in 2026?

Yes — when the conditions described above are met. To break that down further, three things have to be true for a specific compounded enclomiphene prescription to be legal:

1. A valid prescriber-patient relationship. The prescriber must have evaluated the specific patient — not run a checkbox intake form — and concluded that compounded enclomiphene is appropriate. This individualized evaluation is what makes the prescription patient-specific under 503A. Telehealth relationships can satisfy this in many states, but the standards vary.
2. A licensed compounding pharmacy. The dispensing pharmacy must hold a current state license and (for 503B office stock) be FDA-registered as an outsourcing facility. Verification can be done via the state board of pharmacy and the FDA outsourcing facility registry.
3. Compliance with FDA bulks list and compounding restrictions. The active pharmaceutical ingredient must be obtained from an FDA-registered API supplier, and the substance must qualify under one of the regulatory pathways for compounding (bulks list inclusion, USP monograph, or component-of-approved-drug analysis).

Compounded enclomiphene that meets these three conditions is legal in 2026. It is not, however, FDA-approved — those are different statements, and the difference matters for product expectations. A compounded preparation does not carry the formal cGMP, bioequivalence, and post-market surveillance guarantees of an FDA-approved product.

Telehealth, the prescriber relationship, and the legal gray zone

The 2020-2024 expansion of telehealth changed how many men access enclomiphene. A typical pathway in 2026 looks like: a man fills out an online intake form on a men's health telehealth platform, submits lab work or completes a draw via partner phlebotomy, has a brief asynchronous or synchronous consultation with a licensed prescriber, and receives a prescription that the platform routes to a partner 503A compounding pharmacy.

This pathway is legal when each piece is done correctly, but the gray zone in the literature and in state board enforcement focuses on the depth of the prescriber-patient relationship. Some state boards take a stricter view of asynchronous telehealth and intake-form-only evaluations than others. The standards have been clarified by the Federation of State Medical Boards and various state-level telemedicine practice acts, but the variation across states is real.

For a patient, two practical implications follow. First, enclomiphene obtained through telehealth is typically dispensed via compounding — the regulatory framework above applies. Second, the legitimacy of the prescription depends on the prescriber relationship being substantive, not the existence of a generic intake flow. Patients who want maximum confidence in the prescription pathway often work with a urologist, endocrinologist, or men's health-focused physician with whom they have a longer-term relationship.

Risks specific to compounded enclomiphene

Compounded preparations carry a different risk profile than approved drugs. None of these risks make compounded enclomiphene unusable — they shape how patients should think about expectations and monitoring.

• Lack of formal pharmacokinetic studies on the compounded dosage form. The PK data for enclomiphene comes primarily from the Repros Phase 2 and Phase 3 program using a specific formulation. A compounded capsule from a 503A pharmacy may release the API differently. The clinical effect is generally similar, but the rigorous PK evidence does not extend to every compounded version.
• Variability across pharmacies. Two compounding pharmacies can produce 12.5 mg enclomiphene capsules with different excipients, different release profiles, and different lot-to-lot variation. The USP standards put a floor under this, but the ceiling is lower than for cGMP-manufactured products.
• Limited adverse event reporting infrastructure. FDA-approved drugs feed into FAERS (FDA Adverse Event Reporting System) with structured manufacturer reporting. Compounded products have a thinner reporting infrastructure, which makes signal detection slower if a population-level issue emerges.
• Insurance coverage variability. Some insurance plans do not cover compounded medications at all, others cover them with prior authorization, and pricing varies widely.
• Ingredient sourcing. Reputable 503A and 503B pharmacies source API from FDA-registered suppliers. Less reputable sources sometimes appear; this risk is patient-side mitigated by working with verified pharmacies.

For monitoring schedules that apply broadly to enclomiphene therapy regardless of formulation source, see TRT blood work schedule and SHBG and testosterone.

When will enclomiphene be FDA-approved?

There is no public FDA approval timeline. Marius's public communications focus on advancing the RESTORE Phase 3 program through enrollment and follow-up, with NDA timing dependent on the trial readout. Standard regulatory timelines provide a useful reference frame.

A reasonable best-case sequence — assuming RESTORE proceeds without major hiccups — looks like:

1. Complete recruitment.
2. Complete the planned treatment-and-follow-up duration.
3. Database lock and primary analysis.
4. NDA submission (typically 6 to 12 months after primary readout to assemble the dossier).
5. FDA standard review: 10 months from NDA filing (Class 1 resubmission) or 6 months under Priority Review if granted.
6. FDA action: approval, Complete Response Letter, or other outcome.

Telescoping that pipeline against the RESTORE 2026 status, the earliest plausible FDA approval falls in late 2027 if everything goes well, with 2028 to 2029 the more credible expectation. This is an estimate based on standard regulatory timelines, not a Marius commitment or an FDA prediction. Recruitment delays, additional FDA requests, or trial-design changes could shift the timeline meaningfully.

The other variable is the FDA Drug Compounding Advisory Committee process and any bulks list determinations that affect compounded enclomiphene supply between now and an eventual approval. The 2023-2025 FDA actions on compounded peptides (notably semaglutide and tirzepatide compounding restrictions following each drug's coming off the FDA shortage list) and on selected SARMs provide a parallel pattern: regulatory clarity tends to tighten as approved alternatives become available, and compounding access can change quickly. A Marius approval would likely shift the compounded landscape, since compounding generally cannot continue once an FDA-approved equivalent exists.

What this means for patients on enclomiphene now

For a man currently receiving compounded enclomiphene through a legitimate prescriber and pharmacy, the practical message is straightforward: the pathway is legal, the prescription is valid, and the medication can continue under prescriber supervision. The regulatory framework is not in itself a reason to discontinue therapy. The framework does inform how patients should think about a few specific scenarios.

Scenario 1: Considering enclomiphene for the first time

Confirm the prescriber-patient relationship is substantive (not a five-minute intake form). Verify the dispensing pharmacy's state license and 503A or 503B status. Discuss with the prescriber whether RESTORE trial enrollment is an option — trial participation typically provides FDA-overseen pharmacovigilance, no out-of-pocket drug cost, and structured monitoring, though it requires accepting the trial randomization and protocol.

Scenario 2: Currently on compounded enclomiphene

Continue with prescriber supervision. Note the dispensing pharmacy and verify its credentials annually. Watch FDA Drug Compounding Advisory Committee announcements for any bulks list changes that could affect supply. Maintain monitoring labs on the schedule the prescriber recommends.

Scenario 3: Following the RESTORE trial

ClinicalTrials.gov is the authoritative source for RESTORE recruitment status, eligibility criteria, and site list. Marius press releases and SEC filings (if Marius issues public reports) supplement this. FDA approval announcements, when they come, will appear on the FDA Drugs@FDA database and the FDA press release feed.

Scenario 4: Comparing enclomiphene to TRT

Regulatory status is one factor among several. The mechanistic, clinical, fertility-preservation, and lifestyle differences are at least as important. Enclomiphene vs TRT covers that comparison directly. Clomid vs TRT covers the related clomiphene mixture comparison. Coming off TRT covers HPTA recovery, which is relevant when transitioning between treatment paradigms.

Frequently asked questions

Is enclomiphene FDA-approved 2026?

No. As of May 2026, no enclomiphene product holds FDA approval. The Marius Pharmaceuticals RESTORE Phase 3 trial is the active development program seeking approval, but no NDA has been filed and no approval has been granted. Every enclomiphene prescription dispensed in the United States in 2026 is either compounded by a licensed pharmacy or part of the RESTORE clinical trial.

Why is enclomiphene not approved?

The Repros Therapeutics Androxal NDA, filed in late 2015, received a Complete Response Letter from the FDA in 2016 requesting additional efficacy evidence on the sperm-preservation claim that differentiated Androxal from existing testosterone replacement therapies. Repros could not fund follow-up trials and filed for Chapter 11 bankruptcy in 2018. The current Marius RESTORE Phase 3 program is designed to address the FDA's 2016 efficacy questions, but it has not yet completed enrollment or follow-up.

Is compounded enclomiphene legal?

Yes, with conditions. Compounded enclomiphene is legal when there is an individualized prescription from a licensed prescriber based on a documented patient evaluation, the dispensing pharmacy is a state-licensed 503A pharmacy or an FDA-registered 503B outsourcing facility, and the bulk drug substance complies with FDA bulks list determinations. The legality is conditional on these factors — not unconditional. Section 503A of the Federal Food, Drug, and Cosmetic Act governs the patient-specific compounding pathway.

When will enclomiphene be approved?

There is no public timeline. The Marius RESTORE Phase 3 trial is recruiting in 2026; standard regulatory timelines suggest the earliest plausible FDA approval is late 2027, with 2028 to 2029 the more credible expectation. This is an estimate based on typical Phase 3 to NDA to FDA review durations, not a commitment from Marius or a prediction from the FDA.

What was Androxal?

Androxal was Repros Therapeutics' brand name for enclomiphene citrate, developed for the treatment of secondary hypogonadism in men. The Phase 3 program (ZA-301 and ZA-302) reported in 2014 to 2015. The NDA was submitted in late 2015 and received a Complete Response Letter from the FDA in 2016. Repros's Chapter 11 bankruptcy in 2018 ended the original Androxal program; the IP eventually moved to Marius Pharmaceuticals via the bankruptcy estate and subsequent transactions, where it became the basis for the RESTORE Phase 3 program.

Does the FDA Drug Compounding Advisory Committee review enclomiphene?

The Pharmacy Compounding Advisory Committee (PCAC) reviews bulk drug substances proposed for inclusion on the 503A and 503B bulks lists. Enclomiphene's status has been the subject of PCAC review meetings whose minutes and votes are part of the public FDA record. The committee's recommendations inform but do not bind FDA decisions. Patients and prescribers tracking the regulatory landscape can review PCAC meeting materials at fda.gov/advisory-committees/human-drug-advisory-committees/pharmacy-compounding-advisory-committee.

The bottom line

Enclomiphene is not FDA-approved as of 2026, and there is no active NDA filing under FDA review. The most-cited approval attempt — Repros Therapeutics' Androxal program — ended after a 2016 Complete Response Letter requesting additional efficacy evidence on the sperm-preservation claim and Repros's 2018 Chapter 11 bankruptcy. The active development program is Marius Pharmaceuticals' RESTORE Phase 3 trial, which is recruiting at multiple U.S. sites and tracked on ClinicalTrials.gov.

Despite the lack of approval, enclomiphene is widely available in 2026 — almost entirely through 503A and 503B compounding pharmacies dispensing patient-specific or office-stock preparations under licensed prescriptions. The legal framework rests on three conditions: a substantive prescriber-patient relationship, a properly licensed compounding pharmacy, and compliance with FDA bulk drug substance rules. Compounded enclomiphene meeting these conditions is legal but is not the same product as a hypothetical FDA-approved enclomiphene would be — formal cGMP manufacturing, bioequivalence, FDA-reviewed labeling, and structured post-market surveillance are all parts of the approved-drug system that compounding does not fully replicate.

The regulatory landscape is not static. The RESTORE trial readout, the FDA Drug Compounding Advisory Committee's ongoing bulks list reviews, and the FDA's broader 2023-2025 enforcement pattern on compounded peptides and androgen-pathway drugs together shape what enclomiphene access looks like over the next several years. Patients on enclomiphene now should keep a working understanding of the framework, work with prescribers and pharmacies whose credentials they have verified, and watch the FDA Drugs@FDA database for an eventual approval announcement.